Raymond James Financial Services Advisors Inc. Trims Holdings in DexCom, Inc. (NASDAQ:DXCM)

Posted by on May 15th, 2023

Raymond James Financial Services Advisors Inc. decreased its holdings in DexCom, Inc. (NASDAQ:DXCM – Get Rating) by 1.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 97,895 shares of the medical device company’s stock after selling 976 shares during the period. Raymond James Financial Services Advisors Inc.’s holdings in DexCom were worth $11,086,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Parnassus Investments LLC purchased a new position in shares of DexCom during the fourth quarter valued at $214,000. Lindbrook Capital LLC increased its stake in shares of DexCom by 40.2% during the fourth quarter. Lindbrook Capital LLC now owns 1,471 shares of the medical device company’s stock valued at $167,000 after buying an additional 422 shares during the period. Van ECK Associates Corp increased its stake in shares of DexCom by 70.2% during the fourth quarter. Van ECK Associates Corp now owns 10,629 shares of the medical device company’s stock valued at $1,204,000 after buying an additional 4,385 shares during the period. Capital CS Group LLC purchased a new position in DexCom in the fourth quarter valued at about $301,000. Finally, Connor Clark & Lunn Investment Management Ltd. grew its stake in DexCom by 59.2% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 30,118 shares of the medical device company’s stock valued at $2,426,000 after purchasing an additional 11,205 shares during the last quarter. Hedge funds and other institutional investors own 94.01% of the company’s stock.

DexCom Stock Up 0.5 %

NASDAQ DXCM opened at $121.70 on Monday. The business has a fifty day moving average price of $116.91 and a 200 day moving average price of $114.33. DexCom, Inc. has a one year low of $66.89 and a one year high of $126.44. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.82 and a current ratio of 2.02. The company has a market cap of $47.18 billion, a P/E ratio of 173.86 and a beta of 1.16.

DexCom (NASDAQ:DXCM – Get Rating) last issued its earnings results on Thursday, April 27th. The medical device company reported $0.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.15 by $0.02. DexCom had a return on equity of 18.29% and a net margin of 9.68%. The business had revenue of $7.45 billion during the quarter, compared to the consensus estimate of $720.52 million. During the same period last year, the company earned $0.08 EPS. The company’s revenue for the quarter was up 1085.0% on a year-over-year basis. Research analysts anticipate that DexCom, Inc. will post 1.06 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have issued reports on DXCM shares. Stifel Nicolaus lifted their target price on DexCom from $130.00 to $140.00 in a research note on Friday, April 28th. Raymond James upped their target price on DexCom from $138.00 to $140.00 in a research report on Friday, April 28th. StockNews.com upgraded DexCom from a “hold” rating to a “buy” rating in a research report on Monday, May 1st. Wolfe Research began coverage on DexCom in a research report on Thursday, January 26th. They issued an “outperform” rating and a $121.00 target price on the stock. Finally, UBS Group upped their price objective on DexCom from $142.00 to $150.00 in a research report on Friday, April 28th. Two equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, DexCom has a consensus rating of “Moderate Buy” and an average price target of $126.81.

Insider Buying and Selling

In related news, SVP Matthew Vincent Dolan sold 226 shares of the firm’s stock in a transaction dated Monday, March 6th. The stock was sold at an average price of $114.40, for a total transaction of $25,854.40. Following the completion of the sale, the senior vice president now directly owns 26,536 shares of the company’s stock, valued at approximately $3,035,718.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Steven Robert Pacelli sold 412 shares of DexCom stock in a transaction dated Thursday, February 23rd. The stock was sold at an average price of $111.64, for a total value of $45,995.68. Following the completion of the transaction, the director now owns 136,464 shares in the company, valued at approximately $15,234,840.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Matthew Vincent Dolan sold 226 shares of DexCom stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $114.40, for a total value of $25,854.40. Following the completion of the transaction, the senior vice president now owns 26,536 shares of the company’s stock, valued at approximately $3,035,718.40. The disclosure for this sale can be found here. In the last ninety days, insiders sold 141,835 shares of company stock valued at $16,433,574. 0.41% of the stock is currently owned by insiders.

DexCom Company Profile

(Get Rating)

DexCom, Inc is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F.

Read More

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM – Get Rating).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.